BETA BIONICS INC (BBNX)
Sector: Health Care
2026 Annual Meeting Analysis
BETA BIONICS INC · Meeting: May 21, 2026
Directors FOR
1
Directors AGAINST
1
Say on Pay
AGAINST
Auditor
FOR
Director Elections
Election of Two Class I Directors
Against Analysis
Sean Carney has served since February 2020 and fully overlaps the period during which BBNX's stock fell approximately 62.5%, trailing the IHI (iShares US Medical Devices ETF) by about 61.5 percentage points over three years — well above the 30-point threshold our policy sets for companies with negative absolute returns — and the five-year track record shows the same degree of underperformance, so no long-term mitigant applies.
For Analysis
Christy Jones joined the board in January 2025, which is within the 24-month window our policy uses before holding a new director accountable for prior stock performance; she is therefore exempt from the TSR underperformance trigger, all other governance screens (independence, attendance, overboarding, qualifications) are clear, and a FOR vote is appropriate.
Of the two Class I director nominees, Sean Carney receives an AGAINST vote because he has served since 2020 and bears full accountability for BBNX's severe and sustained stock underperformance relative to the IHI (iShares US Medical Devices ETF); Christy Jones receives a FOR vote because she joined in January 2025 and is within the 24-month new-director exemption from the TSR trigger.
Say on Pay
✗ AGAINSTCEO
Sean Saint
Total Comp
$12,191,317
Prior Support
N/A
CEO Sean Saint received total compensation of $12,191,317 in 2025, dominated by a large option grant valued at nearly $8 million at the time of the IPO — but BBNX's stock has since fallen approximately 48% from the $17.00 IPO price to $8.86, meaning shareholders have experienced severe losses while executives received substantial awards. BBNX's 3-year stock return of -62.5% trails the IHI (iShares US Medical Devices ETF) by approximately 61.5 percentage points, far exceeding our 20-point threshold for pay-for-performance misalignment when variable pay is above benchmark. Combined with a 40% base salary increase for the CEO in the same year the stock declined sharply, the compensation program fails our pay-for-performance alignment test and warrants an AGAINST vote.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
3 yrs
Audit Fees
$677,399
Non-Audit Fees
$71,269
Ernst & Young LLP has served as BBNX's auditor since 2023 (approximately three years), well below the 25-year tenure threshold that would raise independence concerns; non-audit fees (tax services of $71,269) represent about 10.5% of audit fees of $677,399, comfortably below the 50% threshold; EY is a Big 4 firm appropriate for this company's size and complexity; no material restatements are disclosed, so all policy screens are clear and a FOR vote is warranted.
Overall Assessment
The 2026 Beta Bionics annual meeting presents two proposals: a director election where one of two nominees (Sean Carney) receives an AGAINST vote due to sustained severe stock underperformance relative to the IHI (iShares US Medical Devices ETF) during his tenure, and auditor ratification of Ernst & Young which passes all policy screens cleanly. The Say on Pay vote receives an AGAINST determination due to a large CEO pay package — including an IPO-related option grant — that is deeply misaligned with shareholder outcomes given the stock's 62.5% decline over three years and its current price well below the IPO grant price.